Enara Bio is a biopharmaceutical company developing next-generation cancer immunotherapies for solid tumours. The business focuses on discovering and validating Dark Antigens, novel cancer-specific targets derived from previously unexplored regions of the genome. Its proprietary EDAPT platform identifies and validates these targets, while its EnTiCE platform is used to optimise bispecific T-cell engagers designed to direct immune responses against cancer cells. Enara Bio is building a pipeline of first-in-class therapies, including programmes targeting DARKFOX, and also works through collaborations with pharmaceutical and academic partners. It operates in the biotechnology and immuno-oncology industry.
